Contributor Page
Smart & Biggar/Fetherstonhaugh
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
ON M5H 3S5
By Brandon Heard
Health Canada recently published two guidance documents, effective May 23, 2018, that address the reporting of adverse reactions to marketed health products (excluding blood and blood components and cells, tissues and organs).
By Urszula Wojtyra
On June 15, 2018, Health Canada announced the publication of proposed Regulations Amending the Food and Drug Regulations and the Regulations Amending the Medical Devices Regulations.
By Christine Genge
On June 27, 2018 the Government of Canada published the new Industrial Design Regulations in the Canada Gazette and set November 5, 2018 as the date on which amendments to the Industrial Design Act and Regulations will come into force.
By Abigail Smith
Health Canada has issued updated guidance reflecting the September 21, 2017 amendments: Guidance Document: Patented Medicines (Notice of Compliance) Regulations (see our summary of the amendments here).
By Urszula Wojtyra
Further to our update in December 2017, here, below is a mid-year update on biosimilar approvals, litigation and other news.
By Alice Tseng, Graham Hood
After an unpredictable few weeks, Bill C-45, the Cannabis Act, received Royal Assent on June 21, 2018, and adult use cannabis will be legal in Canada as of October 17, 2018.
By Mark Biernacki, Guillaume Lavoie Ste-Marie, Joshua Neubarth
In most jurisdictions, copyright owners often face numerous challenges when seeking to enforce their rights against media pirates.
By Daniel Anthony, Jamie-Lynn Kraft
As trade talks between Canada and the United States dominate the headlines, it is hard to ignore the strong economic ties between these neighbouring nations.
By Brandon Heard
On April 23, 2018, the Competition Bureau announced an agreement whereby Metro will sell properties/leases and take steps to terminate agreements relating to pharmacies in certain Quebec markets.
By Brandon Heard
The balance of Pfizer's motion to dismiss has been deferred to the trial in the liability phase of the proceeding.
By Andrew Mandlsohn
Eli Lilly seeks leave in olanzapine section 8 damages action.
By Abigail Smith
The report of the Working Group will be presented to the PMPRB for consideration prior to the publication of draft Guidelines in the fall, followed by a further period of consultation.
By Lynn Ing
These provisions will not come into force until October 23, 2018.
By Katie Lee
Eliminate the requirement for filing clinical case reports in a filed submission or supplement, unless requested by the Minister, in order to alleviate administrative burden.
By Katie Lee
We will continue to report updates as further regulations and guidance arise.